In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.
about
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytesSynthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTLImmunologic aspect of ovarian cancer and p53 as tumor antigen.T cell avidity and tumor recognition: implications and therapeutic strategies.Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 moleculesTargeting p53 as a general tumor antigen.A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.Immunotherapy of brain cancers: the past, the present, and future directions.Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopesThe role of p53 in the immunobiology of cutaneous squamous cell carcinoma.Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccinesUse of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytesTolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope.Tumor antigens discovery: perspectives for cancer therapy.Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.Molecular alterations in pediatric sarcomas: potential targets for immunotherapyDendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitroSpontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.Identification of the promoter of the mouse obese gene.Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients.HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides.Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8.HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line.Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens.Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms.Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms.In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen.Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
P2860
Q24680097-71F136C6-A3F1-4201-9039-278B236A1CB4Q24684276-9BE0EA73-B722-489D-8604-6430D61C0B43Q24814703-057F0CBA-7346-49C1-AB68-05F349C94BB2Q24815775-D1E88CDB-8A41-4B30-B650-19020E6F8A75Q27478466-D280ACA7-E77F-42EA-9D35-C3EB1CBDA342Q33638172-A9317586-B4A9-4089-B354-A572D1481993Q34021153-62A15BA9-8818-4295-9B15-4959823F6995Q34657661-F39636D3-D6D4-4E9C-AF87-29AFC043735AQ34701587-098249FD-92A5-453E-A8C8-8BF16B375E2CQ34898280-7D017D79-8EEC-465E-811D-A84B482D3B16Q35093159-FEEE6844-0BCD-4AC7-9E4D-8BDB08DA930BQ35142669-DFF0F9CC-D354-4449-9343-755F7F3735D9Q36364998-47888B2C-E8E4-4179-BEF9-AD5E7E7ACE2BQ36365932-90C430F6-10FC-43E0-AF99-F92426B4AB83Q36366405-CE9D7DEF-69BE-49E6-B94A-98496E140535Q36367022-9AD72B20-907E-47EA-BCC7-886D59BBC48BQ36376876-C352D27A-29F4-4B15-81A5-2B3D7A32780BQ36380515-7349DF52-451E-4EB0-BB6F-8FA58962A23FQ36401780-C49849F3-1291-42AE-826B-5E8AE639922DQ36438078-C5CE6C39-8C3D-449B-B124-04F804C9A579Q36470715-FCA91248-2CF5-4FDD-93CC-72E26D2B8A0BQ36673885-205D5D6A-4031-469F-970F-4D24E8869ABFQ36924579-500EE3DC-DAEA-486E-84AF-E6EA96063B93Q37049451-C2C5F903-C03F-4980-AB4B-3B40B6292343Q37375709-945525C4-C1C0-4915-96D6-35EE05BBBA53Q37604767-8DE6A1C1-47B1-4E86-8866-5D490FAB0410Q37629731-49459E24-68B8-4A0D-A667-DB12542BBD22Q37629901-D427C278-47B4-4E1D-8CC8-5C58B4C1C907Q40555883-4E3A44F4-4EF9-444D-AA3A-06FC6D2ED950Q40616543-3CF7F56C-88CF-4AD5-A1CC-BE830E4B17FEQ40720422-A641BEE5-F10C-4054-A285-E5B6B1AAC4A3Q40738759-39E8E2CA-82E1-4457-8A34-5E683A06C61CQ40784250-BDE9C625-5998-46B2-8C41-81E491D0ED95Q40801080-8422347D-0ADE-48A4-9D5E-F6A53F043139Q40903376-0773755B-C81B-42FE-9A91-FF69E2ECAC33Q41005830-3BF5DA7C-4F9C-4D87-9E25-15821A45E8B2Q41062756-3764F4AF-BB2C-4B2B-8F14-D1E66D207109Q41127128-0FC287F5-9EAA-43BE-90D2-8E1F49085F23Q41130455-1F3F2F61-D895-4EB2-B328-18A737A1BFDDQ41342823-7C86CF5D-E6C6-411F-903A-A53E70429827
P2860
In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
In vitro induction of human cy ...... s of mutant and wild-type p53.
@en
type
label
In vitro induction of human cy ...... s of mutant and wild-type p53.
@en
prefLabel
In vitro induction of human cy ...... s of mutant and wild-type p53.
@en
P2093
P356
P1476
In vitro induction of human cy ...... s of mutant and wild-type p53.
@en
P2093
Drijfhout JW
Houbiers JG
Kenemans P
van de Velde CJ
van der Burg SH
P304
P356
10.1002/EJI.1830230905
P407
P577
1993-09-01T00:00:00Z